Economic Burden of Multiple Sclerosis on patients: Research Findings from Greece

Athanassios Vozikis^1, and Eleni Sotiropoulou²

¹Economics Department, University of Piraeus, Piraeus, Greece

²Informatics Department, University of Piraeus, Piraeus, Greece

Cite this paper:
Athanassios Vozikis and Eleni Sotiropoulou. Economic Burden of Multiple Sclerosis on patients: Research Findings from Greece. Journal of Finance and Economics. 2013; 1(3):36-40. doi: 10.12691/jfe-1-3-2

Abstract

The Multiple Sclerosis (MS) is a chronic autoimmune, inflammatory disease, which is the third cause of serious disability for the ages between 20 and 40 years old. More than 8,000 Greeks suffer from this disease. The scope of our research is to estimate the economic burden on patients with MS, through the analysis of their out - of - pocket payments. The study was conducted in 2010 to a random sample of 400 patients, from whom 288 (103 men and 185 women) completed the research questionnaire. The average annual out - of - pocket payments of MS patients, found to be 8,334€, significantly varying by the gender and the severity of the disease. From our research it was unveiled the significant economic burden on patients with MS in Greece. Consequently, it is appointed the imperative need of research on the social and economic cost of MS and of introducing an integrated support system for the patients.

Keywords:
multiple sclerosis health economics out - of- pocket payments cost of illness Greece

This work is licensed under a Creative Commons Attribution 4.0 International License. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/

Figures

References:

[1]	Meader R.: Does the history of MS go back as far as the 14th century? ActaNeurol Scan. 60, 189-192 (1979).
[2]	Papadopoulou X.: Answers to common questions for MS. Communicate. 7, 3-6 (2008).
[3]	Newman JP, Maccoon DG, Vaughn LJ, Sadeh N.: Validating a distinction between primary and secondary psychopathy with measures of Gray's BIS and BAS constructs.J Abnorm Psychol. 114(2), 319-23 (2005).
[4]	Traka M, Kraki E, Kygitsidou E, Patsiou A, Costa B, Baloyannis S.I.:Dystonic phenomena in MS patients hospitalized during 1992 – 2002, in the 1st Department of Neurology of Aristotelian University of Thessaloniki, Archives of Neurology and Psychiatry. Encephalos. 4(41), 1-4 (2004).
[5]	Prineas J, Wright RG.: Macrophages, lymphocytes and plasma cells in the perivascular compartment in chronic multiple sclerosis. Lab Invest. 38, 409-421 (1978)
[6]	Koutsouraki E.: Living with MS. Impact on the family. Communicate. 8, 6-8 (2008).
[7]	Zervas K.: The phenomenology of Chronic illness: The study of MS. Graduate Thesis Submitted for the degree of Msc in Health Care Management. Hellenic Open University. (2003).
[8]	MULTIPLE SCLEROSIS INTERNATIONAL FEDERATION (MSIF). Disease courses in MS, MS in focus. 14, 4-14 (2009).
[9]	DrΤermou Α.: Recent opinions and responses to gynecologic and obstetrics problems of demyelinating disease. Communicate. 10, 4-7 (2009).
[10]	Koutsis G, Panas M.: Recent findings in the genetics of Multiple Sclerosis. Archives of Hellenic Medicine. 2, 135-150 (2008).
[11]	Polikandrioti M, Kyritsi H.: Quality of life of patients with MS, Review. Nosileftiki. 45, 207-214 (2006).
[12]	KurtzkeJF.: Epidemiology and etiology of Multiple Sclerosis. Phys Med RehabilClin N Am. 16, 327-349 (2005).
[13]	Gourzoulidou EP.: Multiple Sclerosis in Western Greece – Epidemiology of the disease and clinical study of the patients. Ph. D. Thesis. Faculty of Medicine. University Patras. 15-16(2008).
[14]	Rabanis C.: MS: Social and Ρsychological aspects: Athens. Nissos Academic Publishing. 55 (2009).
[15]	Papavasiliou A.: Early onset MS. Communicate. 8, 12-14 (2008)
[16]	Henriksson F, Jonsson B.: The economic evaluation and consequences of multiple sclerosis. International MS Journal/MS Forum. 7(1), 9-17 (2008).
[17]	KurtzkeJF.:Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology. 33(11), 1444–1452 (1983).
[18]	KurtzkeJF.:A new scale for evaluating disability in multiple sclerosis. Neurology. 5, 580–583 (1995)
[19]	Henriksson F, Fredrikson S, Masterman T, Jonsson B.: Costs quality of life and disease severity in multiple sclerosis: a cross sectional study in Sweden. Eur Neurol. 8, 27-35 (2001).
[20]	Kobelt G, Berg J, Lindgren P, Fredrikson S, Jonsson B.: Costs and quality of life of patients with multiple sclerosis in Europe. J NeurolNeurosurg Psychiatry.77, 918-926 (2006).
[21]	Kobelt G, Lindgren P, Parkin D, Francis D, Johnson M, Bates D, Jonsson B.: Costs and Quality of life in multiple sclerosis: A Cross - Sectional Observational Study in the UK (This report is part of an observational study in three countries). Stockholm School of Economics Working Paper Series in Economics and Finance.398-399 (2000).
[22]	Kobelt G, Lindgren P, Smala A, Jonsson B, THE GERMAN COST of MS STUDY GROUP.: Costs and Quality of life in multiple sclerosis: A Cross - Sectional Observational Study in the Germany (This report is part of an observational study in three countries). Stockholm School of Economics. Working Paper Series in Economics and Finance.399 (2000).
[23]	Ceri JP, Humphreys I.: Assessing cost-effectivess in the management of multiple sclerosis.ClinicoEconomics and Outcomes research. 1, 61-78 (2009).
[24]	Casado V, Martinez YS, Martinez YA, Carmona V, Alonso L, Romero L, Moral E, Gubieras L, Arbizu T.: Direct and indirect costs of Multiple Sclerosis in BaixLiobregat (Catalonia, Spain), according to disability. BMC Health Service Research. 6, 143 (2006).
[25]	Kobelt G, Berg J, Lindgren P, Decoo D, Guillaume D, Neymark N, et al.: Costs and quality of life for patients with multiple sclerosis in Belgium.Eur J Health Econ.7, 24-33 (2006).
[26]	Kobelt G, Berg J, Lindgren P, Elias WG, Flackenecker P, Friedel M, et al.: Costs and quality of life for patients with multiple sclerosis in Germany. Eur J Health Econ. 7, 34-44 (2006).
[27]	Trisolini M, Honeycutt A, Wiener J, Lesesne S.:Global economic impact of Multiple Sclerosis. ΜSIF. London. United Kingdom. 22-68 (2010).
[28]	Orologas Α, Thomaidis G, Baloyianni Ε, Kalpatsanidis Α, Daglis Ι, Tsantaki Ε.:The economic and social impacts of MS in Greece– Pilot study, 24th annual congress of the Hellenic Neurological Society. Kos. 20th -23rd May (2010).
[29]	KurtzkeJF.:Georgaphic distribution of multiple sclerosis: an update with reference to Europe and the Mediterranean region. ActaNeurol Scand. 62, 65-80 (1980).
[30]	Vickrey BG, Hays RD, Harooni R, Meyers LW.: A health related quality of life measure for multiple sclerosis. Qual Life Res. 4(3), 187-206 (1985).
[31]	Hobart J, Lamping D, FitzpatrickR, RiaziA, ThompsonA.: The Multiple Sclerosis Impact Scale (MSIS-29). A new patient – based outcome measure. Brain. 124, 962-973 (2001).
[32]	Andlin-Sobocki P, Jonsson B, Wittchen HU, Olesen J.:Costs of Disorders of the Brain in Europe. European Journal of Neurology, 12(1), 63-67 (2005).
[33]	KapinaΒ.: The working ability of patients suffering from MS: Correlation of clinical, psychological and neuroradiological parameters. Ph. D. Thesis. Faculty of Medicine. Aristotle University of Thessaloniki. 102-116 (2009).